EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease

Shahida Din, Christian P Selinger, Christopher J Black iD, Alexander C Ford iD

Alimentary Pharmacology & Therapeutics · 2023-03 · 57 (6) · 666-675

DOI: 10.1111/apt.17379 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 31.12.2022. Verfasst von Shahida Din und 3 weiteren Autor:innen. Beteiligte Einrichtung: Edinburgh Inflammatory Bowel Diseases Unit, Western General Hospital, Edinburgh, UK. Hauptthemen laut MEDLINE: Crohn Disease, Herpes Zoster, Inflammatory Bowel Diseases, Janus Kinase Inhibitors. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologics and small molecules for inflammatory bowel disease (IBD) may increase infection risk. Herpes zoster causes acute and long‐term symptoms, but vaccination is not recommended in patients with IBD, unless >50 years of age.

Aims

To examine risk of Herpes zoster infection with all licensed biologics and small molecules for IBD using network meta‐analysis.

Methods

We searched the literature to 4th October 2022, for randomised controlled trials of these drugs in luminal Crohn's disease or ulcerative colitis reporting data on occurrence of Herpes zoster infection during follow‐up. We used a frequentist approach and a random effects model, pooling data as relative risks (RRs) with 95% confidence intervals (CIs).

Results

We identified 25 trials (9935 patients). Only tofacitinib 10 mg b.d. (RR = 6.90; 95% CI 1.56–30.63, number needed to harm (NNH) = 97; 95% CI 19–1022) and upadacitinib 45 mg o.d. (RR = 7.89; 95% CI 1.04–59.59, NNH = 83; 95% CI 10–14,305) were significantly more likely to increase risk of Herpes zoster infection. Janus kinase inhibitors were the most likely drug class to increase risk of infection, and risk increased with higher doses (RR with lowest dose = 3.16; 95% CI 1.02–9.84, NNH = 265; 95% CI 65–28,610, RR with higher dose = 5.91; 95% CI 2.21–15.82, NNH = 117; 95% CI 39–473).

Conclusions

In a network meta‐analysis, the janus kinase inhibitor tofacitinib, and all janus kinase inhibitors considered as a class, were most likely to increase risk of Herpes zoster infection. Risk increased with higher doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseHerpes ZosterInflammatory Bowel DiseasesJanus Kinase InhibitorsHumansBiological Therapy

Stichwörter der Autor:innen

Herpes zosterRCT comparisoninfectioninflammatory bowel diseasesafety

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Edinburgh Inflammatory Bowel Diseases Unit, Western General Hospital, Edinburgh, UK.
  • Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
  • Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.

ORCID-Profile: Christopher J Black, Alexander C Ford

Zitieren

APA

Din, S., Selinger, C. P., Black, C. J., & Ford, A. C. (2023). Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 57(6), 666-675. https://doi.org/10.1111/apt.17379

Vancouver

Din S, Selinger CP, Black CJ, Ford AC. Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2023;57(6):666-675. doi:10.1111/apt.17379

BibTeX
@article{Din2023,
  author = {Din, Shahida and Selinger, Christian P and Black, Christopher J and Ford, Alexander C},
  title = {Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {6},
  pages = {666--675},
  doi = {10.1111/apt.17379}
}
Kostenlos starten →